Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stock Crash: Outperforming contract research firm tanks 14% after Q4 results
Ahead of Friday's fall, Sai Life Sciences' shares had surged more than 100% from its IPO price of ₹549, and was also near its 52-week high of ₹1,139.
Five stocks seeing the biggest fall after their Q4 results on Friday
From Sai Life Sciences to Data Patterns, and PN Gadgil Jewellers, these five stocks are seeing the biggest negative reaction to their March quarter results that were reported after market hours on Thursday.
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectations - Investing.com India
Earnings call transcript: Achieve Life Sciences beats Q1 2026 EPS expectationsInvesting.com India
Sai Life Sciences consolidated net profit rises 18.09% in the March 2026 quarter
Sales rise 3.91% to Rs 602.14 crore
Alivus Life Sciences standalone net profit rises 14.65% in the March 2026 quarter
Sales rise 6.09% to Rs 689.12 crore
Suven Life Sciences reports consolidated net loss of Rs 45.60 crore in the March 2026 quarter
Sales rise 3.40% to Rs 1.52 crore
Fractal Analytics Q4 Results: Profit more than doubles to Rs 116 crore
Fractal Analytics reported a significant financial leap, with its Q4 profit after tax doubling to Rs 116 crore, fueled by an impressive 82% surge in its healthcare and life sciences division. The company's overall revenue also saw a healthy 17% increase. This robust performance, coupled with a debt-free status post-IPO, positions Fractal for continued expansion.
Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?
In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent
Stock market today: Gift Nifty signals gap-up start; election results, India VIX to Q4 results — 7 stocks to buy or sell
Stock market today: Experts recommend these eight stocks to buy today —Sona Blw Precision Forgings, Sai Life Sciences, Reliance, SAIL, GPPL, Thermax, and Tata Capital
Bombay HC backs GSK in Paxil trademark row against Shreya Life Sciences
The Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medicinal preparations. It argued that despite getting the mark more than two decades ago, Shreya Life Sciences had never used it and hence, under Section 47 of the Trade Marks Act, the registration was liable to be removed from the register of trade marks on account of non-use.
RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-September
RPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company also aims to enter the GLP-1 weight-loss therapy market by August-September. Despite geopolitical risks, RPG Life Sciences is strategically focusing on niche, complex molecules and expanding into new therapy areas.
RPG Life Sciences Q4 Results: Operating performance strong, base quarter one-off impacts profit
Shares of RPG Life Sciences Ltd ended at ₹2,024.05, down by ₹34.70, or 1.69%, on the BSE.